This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Bioxytran’s 8K filing here.
About Bioxytran
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
See Also
- Five stocks we like better than Bioxytran
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- How to Plot Fibonacci Price Inflection Levels
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
